PPTA Introduces New Cross Donation Check System

Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) recently launched the Cross Donation Check System (CDCS), a new electronic database designed to assist plasma centers in checking donors more efficiently and effectively.

On Feb. 2, more than 400 plasma collection centers across the United States began using the CDCS, which helps streamline the donation process. The new system reinforces the International Quality Plasma Program (IQPP) Cross Donation Management Standard that was implemented in 2010.

“The development of the CDCS underscores the role of the IQPP Standards Program in helping companies raise the bar for source plasma collection,” said Ileana Carlisle, vice president, Plasma Operations & Logistics, Biotest Pharmaceuticals, and chair of the PPTA IQPP Standards Committee. “Through IQPP, industry has established an innovative and automated solution that further minimizes the risk of cross donation.”  

The CDCS, developed and maintained by Haemonetics, is yet another measure the industry has put in place to protect donors and patients.

“Our IQPP-certified plasma centers are committed to donor health and safety, because without healthy donors, we would not have plasma that is needed to make plasma-derived therapies,” said Shinji Wada, president, Grifols Plasma Operations, and chair of the PPTA Source Board of Directors. “Launching the nationwide Cross Donation Check System takes the industry one step further in its mission to elevate its standards in ensuring the safety of our valuable donors.”

Plasma, a biological material derived from humans, is used to create lifesaving therapies. These plasma protein therapies, which include plasma-derived therapies and recombinant analogs, are used to treat chronic, life-threatening diseases including bleeding disorders, primary immune deficiencies, alpha-1 antitrypsin deficiency and certain rare neurological disorders. In addition, these therapies are used in emergency and surgical medicine.

About PPTA

The Plasma Protein Therapeutics Association (PPTA), a global industry trade association, represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by millions of people worldwide to treat a variety of diseases and serious medical conditions. PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors, and patients. To learn more about plasma protein therapies and the diseases they treat, visit DonatingPlasma.org.

About the PPTA IQPP Voluntary Standards Program

The International Quality Plasma Program (IQPP) is a voluntary certification program for source plasma collection facilities. IQPP certification incorporates a series of standards and objectives relating to the quality of a facility’s donors and its plasma collection operations. People worldwide depend on life-saving therapies derived from human plasma proteins to treat diseases and injuries. Voluntary IQPP standards help ensure that the human source plasma collected is of the highest quality. Centers with IQPP certification are routinely audited for compliance with the standards.

About Haemonetics

Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Haemonetics technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. 

 


 

For additional information contact:
Rachel Liebe
Project Coordinator, Communications
+1.443.433.1118
rliebe@pptaglobal.org